is an advanced stage of prostate cancer High ctDNA% identifies aggressive mCRPC A new tool simplifies ctDNA testing, ensuring timely and accurate prostate cancer management Prostate cancer is the ...
GRAIL, Inc. (Nasdaq: GRAL), a healthcare company whose mission is to detect cancer early when it can be cured, today announced that the first patient has been tested for eligibility with the ...
The research demonstrates how ctDNA and next-generation sequencing (NGS) can drive more personalized and accurate treatment options for cancer patients. "Our presence at AMP 2024 underscores ...